Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruconest for acute hereditary angioedema attacks in children (phase II, open-label)
2011-000987-92Phase 2Completed
- Sponsor
- Pharming Group
- Start
- Jul 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of c1-esterase inhibitor in hereditary angioedema (HAE), sponsored by Pharming Group. Primary endpoint: Safety and tolerability. Started Jul 2011; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2011-000987-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000987-92.